Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Cue Pharma Posts Two Responses From CUE-101 Combo In Head & Neck Cancer

Early data from a trial evaluating Cue Biopharma Inc's (NASDAQ: CUE) CUE-101 combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) demonstrated that two out of four patients in dose-escalation cohorts had partial responses.

  • The other two patients are showing reductions in target lesions.

  • CUE-101, which targets IL-2, is under development as a potential third-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma.

  • CUE-101 + pembrolizumab combination therapy is under examination as a front-line treatment.

  • Updated data on the dose-expansion CUE-101 as a monotherapy trial showed a 50% clinical benefit rate.

  • The Company plans to file an Investigational New Drug (IND) application for CUE-102, another candidate from IL-2 based CUE-100 series, in Q1 of 2022.

  • In January, the Company received a $3 million milestone payment from LG Chem Life Sciences under an agreement for CUE-102.

  • Price Action: CUE shares closed at $10.60 on Wednesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.